Shorts

0:43

Is Proton Therapy Clinically Effective in Breast Cancer?

4 months ago

Chirag Shah, MD

0:44

MajesTEC-3 Trial Shows ‘Remarkable’ Outcomes in R/R Multiple Myeloma

4 months ago

Rajshekhar Chakraborty, MD

During a visit to Columbia University Herbert Comprehensive Cancer Center, CancerNetwork® spoke with Nicole Lamanna, MD, about the implications of the phase 3 AMPLIFY trial (NCT03836261) showing improved efficacy with acalabrutinib (Calquence) plus venetoclax (Venclexta) vs standard of care among patients with chronic lymphocytic leukemia (CLL).

0:31

AMPLIFY Trial Affirms Shift Away From Chemoimmunotherapy in CLL

4 months ago

Nicole Lamanna, MD

Sahil Doshi, MD, discussed the potential for dose reduction strategies with ipilimumab and nivolumab for the treatment of patients with advanced clear cell renal cell carcinoma.

1:14

Considering Reduced Dose Immunotherapy for Frail Metastatic ccRCC Groups

4 months ago

Sahil D. Doshi, MD

In a visit to Columbia University Herbert Irving Cancer Research Center, CancerNetwork® spoke with Brian Henick, MD, about potential adverse effects that may arise with the use of prophylactic steroids for patients who undergo immunotherapy for lung cancer and other diseases.

0:53

Addressing Steroid-Related Toxicities During Immunotherapy for Lung Cancer

4 months ago

Brian Henick, MD

In a recent visit to Columbia University Irving Cancer Research Center, expert researchers and clinicians shared insights on critical therapeutic developments across their respective disciplines.

0:50

Key Advances Across Oncology Research and Care at Columbia University

4 months ago

Russ Conroy

CancerNetwork® spoke with Marc Lehrer Greenwald, MD, about the rising incidence of colorectal cancer among younger patients.

1:09

How a Short Exam Identified a Colorectal Cancer in a Patient in Their 40s

4 months ago

Marc Lehrer Greenwald, MD

In a discussion with CancerNetwork®, Zhaohui Liao Arter, MD, spoke about updated analysis findings from the phase 2 eNRGy trial (NCT02912949) assessing zenocutuzumab-zbco (Bizengri) beyond initial disease progression among patients with NRG1 fusion-positive non–small cell lung cancer.

0:48

Updated Zenocutuzumab Analysis Reveals “Striking” Outcomes in NRG1+ NSCLC

5 months ago

Zhaohui Liao Arter, MD

1:00

The Truth About GLP-1s: Assessing the Risk of Medullary Thyroid Cancer in Humans

5 months ago

Gary Clayman, MD

Marwan G. Fakih, MD, analyzed the current treatment landscape for patients with later-line metastatic colorectal cancer.

1:17

What Are the Best Treatment Options for Patients with Later-Line mCRC?

5 months ago

Marwan G. Fakih, MD

Zin Myint, MD, compared the incidence of AEs among patients with high-risk prostate cancer treated with pembrolizumab and radiotherapy alone vs with olaparib in a phase 2 study.

0:57

Pembro/RT ± Olaparib Shows Similar Safety in High-Risk Prostate Cancer

5 months ago

Zin Myint, MD

In this video, we asked Molly Ingersoll, PhD, a couple of fun, personal questions at ASCO GU.

0:46

GU Gemstones: Molly Ingersoll, PhD

5 months ago

Molly Ingersoll, PhD

$Sagar Lonial, MD, FACP, FASCO, spoke with CancerNetwork® about the FDA’s acceptance of a new drug application for iberdomide plus daratumumab (Darzalex) and dexamethasone for patients with relapsed/refractory multiple myeloma, detailing how a potential approval may impact the treatment paradigm.$

0:46

Iberdomide Might Expand Tool Belt for Finding a Multiple Myeloma Cure

5 months ago

Sagar Lonial, MD, FACP, FASCO

In this pilot "Roman's Rundown" video, Roman introduces KOLs he spoke with at ASCO GU Day 2 and gives a quick, time-lapsed glimpse of his run that morning, which goes right by the conference building.

0:39

Roman's Rundown: ASCO GU Day 2

5 months ago

Roman Fabbricatore

0:55

The Technical Risks of Faster Radiation Treatments in Breast Cancer

5 months ago

Sunil W. Dutta, MD

Jason Molitoris, MD, PhD, discussed the role of intensity-modulated proton therapy as a new standard of care among patients undergoing treatment for oropharyngeal squamous cell carcinoma.

0:38

Defining a New Standard of Care in the OPSCC Treatment Paradigm

5 months ago

Jason K. Molitoris, MD, PhD

0:40

Managing Immunotherapy-Related Toxicities in Breast Cancer

5 months ago

Sarah Poland, MD

Gwen Nichols, MD, spoke with CancerNetwork® about findings from the phase 3 Precision-T trial (NCT04013685) assessing Orca-T vs conventional allogenic hematopoietic stem cell transplantation strategies among patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome.

0:47

Orca-T Reduces the “Costs” of Transplantation in Blood Cancers

5 months ago

Gwen Nichols, MD

In a conversation with CancerNetwork®, Ashkan Emadi, MD, PhD, discussed early findings from a phase 2 trial (NCT07222579) assessing subcutaneous blinatumomab (Blincyto) among patients with CD19-positive mixed phenotype acute leukemia (MPAL), a rare acute leukemia.

0:41

Trial in Rare Leukemia Shows “Unprecedented Result” With Blinatumomab

5 months ago

Ashkan Emadi, MD, PhD

0:59

Can Preoperative Radiation Help Patients Skip Breast Cancer Surgery?

5 months ago

Parul Barry

Monzr M. Al Malki, MD, outlined the advantages TRX103, a novel allogeneic CD4 T-cell therapy, offers for HLA-mismatched hematopoietic cell transplant recipients with lymphoma.

0:39

What Advantages Does TRX103 Provide in HLA-Mismatched Lymphoma?

5 months ago

Monzr Al Malki, MD

Mauro Cives, MD, discussed the advantage a T-cell receptor-based approach affords for patients undergoing treatment for pancreatic neuroendocrine tumors, particularly based on an ability to recognize major histocompatibility complex-presenting intracellular peptides.

1:30

Uncovering the Unique Advantage of a TCR-Based Approach in Pancreatic NETs

5 months ago

Mauro Cives, MD

$In a discussion with CancerNetwork®, Saad Z. Usmani, MD, MBA, FACP, FASCO, outlined the mechanism of action of gintemetostat (KTX-1001), a novel small molecule inhibitor under evaluation in a phase 1 trial (NCT05651932) among patients with relapsed/refractory multiple myeloma.$

0:32

How Does KTX-1001 Target Genetic Abnormalities in Multiple Myeloma?

5 months ago

Saad Z. Usmani, MD, MBA, FACP